Valproic acid capsule/solution contraindications: Difference between revisions
Gerald Chi (talk | contribs) Created page with "__NOTOC__ {{Valproic acid}} {{CMG}} ==Title== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPAKENE (VALPROIC ACID) SOLUTION DEPAKENE (VALPR..." |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Contraindications== | ||
Depakene should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)]. | |||
Depakene is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)]. | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPAKENE (VALPROIC ACID) SOLUTION DEPAKENE (VALPROIC ACID) CAPSULE, LIQUID FILLED [ABBVIE INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b4331f5-4475-417a-6a9d-09c2f8334235 | publisher = | date = | accessdate = }}</ref> | Depakene is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.13)]. | ||
Depakene is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DEPAKENE (VALPROIC ACID) SOLUTION DEPAKENE (VALPROIC ACID) CAPSULE, LIQUID FILLED [ABBVIE INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6b4331f5-4475-417a-6a9d-09c2f8334235 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Latest revision as of 22:11, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Depakene should not be administered to patients with hepatic disease or significant hepatic dysfunction [see Warnings and Precautions (5.1)].
Depakene is contraindicated in patients known to have mitochondrial disorders caused by mutations in mitochondrial DNA polymerase γ (POLG; e.g., Alpers-Huttenlocher Syndrome) and children under two years of age who are suspected of having a POLG-related disorder [see Warnings and Precautions (5.1)].
Depakene is contraindicated in patients with known hypersensitivity to the drug [see Warnings and Precautions (5.13)].
Depakene is contraindicated in patients with known urea cycle disorders [see Warnings and Precautions (5.6)].[1]
References
Adapted from the FDA Package Insert.